{
    "uniprot_canonical_ac": "A0A286Y9T7-1",
    "uniprot_id": [
        {
            "id": "A0A286Y9T7_DANRE",
            "url": "https://www.uniprot.org/uniprot/A0A286Y9T7_DANRE",
            "type": "external"
        }
    ],
    "mass": 97487.0,
    "length": 872,
    "protein_name": "Sema domain, transmembrane domain (TM), and cytoplasmic domain, (Semaphorin) 6Ba precursor; Sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6Ba",
    "gene_name": "sema6ba",
    "organism": "Zebrafish",
    "refseq_name": "sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6Ba precursor",
    "refseq_ac": [
        {
            "id": "NP_001353244",
            "url": "https://www.ncbi.nlm.nih.gov/protein/NP_001353244",
            "type": "external"
        }
    ],
    "gene_names_uniprotkb": "sema6ba; si:ch211-168n16.1",
    "gene_names_refseq": "sema6ba; si:ch211-168n16.1",
    "protein_names_uniprotkb": "Sema domain, transmembrane domain (TM), and cytoplasmic domain, (Semaphorin) 6Ba precursor; Sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6Ba",
    "protein_names_refseq": "sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6Ba precursor; semaphorin 6ba",
    "tax_id": 7955,
    "disease": "progressive myoclonus epilepsy (Disease Ontology:DOID:891)",
    "pathway": "",
    "pathway_count": 0,
    "publication_count": 6,
    "publication_id_list": "22330030;23594743;30004691;32169168;35431796;35585187",
    "function": "##Evidence-Data-START## Transcript exon combination :: GFIL01035691.1 [ECO:0000332] RNAseq introns :: single sample supports all introns SAMEA4476756, SAMEA4476764 [ECO:0000348] ##Evidence-Data-END## VALIDATED REFSEQ: This record has undergone validation or preliminary review. The reference sequence was derived from CU929316.8, CT027824.25 and CT583662.16. On Sep 29, 2018 this sequence version replaced XP_002660976.2. Sequence Note: The RefSeq transcript and protein were derived from genomic sequence to make the sequence consistent with the reference genome assembly. The genomic coordinates used for the transcript record were based on alignments., [RefSeq]",
    "predicted_glycosites": 1,
    "predicted_n_glycosites": 0,
    "predicted_o_glycosites": 1,
    "mined_glycosites": 0,
    "mined_n_glycosites": 0,
    "mined_o_glycosites": 0,
    "reported_n_glycosites": 0,
    "reported_o_glycosites": 0,
    "reported_n_glycosites_with_glycan": 0,
    "reported_o_glycosites_with_glycan": 0,
    "total_reported_n_glycosites": 0,
    "total_reported_o_glycosites": 0,
    "total_n_glycosites": 0,
    "total_o_glycosites": 1,
    "reported_fully_resolved_glycans": 0,
    "reported_phosphosites": 0,
    "reported_mutagensis": 0,
    "reported_glycation": 0,
    "reported_snv": 0,
    "reported_interactions": 0,
    "missing_score": 10000,
    "biomarker_type": "",
    "glycan_count": 0,
    "disease_count": 1,
    "glyco_site_count": 1,
    "binding_glycan_count": 0,
    "secondary_ac_list": "",
    "ec_number_list": [],
    "go_molecular_function": "GO:0030215 semaphorin receptor binding;GO:0045499 chemorepellent activity",
    "go_cellular_component": "GO:0005886 plasma membrane",
    "go_biological_process": "GO:0030335 positive regulation of cell migration;GO:0071526 semaphorin-plexin signaling pathway;GO:0001755 neural crest cell migration;GO:0007411 axon guidance",
    "synthesized_glycan_count": 0,
    "record_id": "A0A286Y9T7-1",
    "record_type": "protein",
    "filter_code": "0000000.0000110.100000.0000000000000001.00010.001"
}